本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担个别及连带责任。 1.经财务部门初步测算，预计2025年年度实现归属于上市公司股东的净利润为500万元到1,000万元，与 上年同期相比，将减少7109.88万元到7609.88万元，同比下降87.67%至93.83%。 2.预计实现归属于上市公司股东扣除非经常性损益的净利润100万元至600万元，与上年同期相比，将减 少294.73万元到794.73万元，同比减少32.94%至88.82%。 重要内容提示： ● 本次业绩预告适用情形：实现盈利，且净利润与上年同期相比下降50%以上。 ● 柳州两面针股份有限公司（以下简称"公司"）预计2025年年度实现归属于上市公司股东的净利润为 500万元到1,000万元，与上年同期相比，将减少7109.88万元到7609.88万元，同比下降87.67%至 93.83%。 公司预计实现归属于上市公司股东扣除非经常性损益的净利润100万元至600万元，与上年同期相比，将 减少294.73万元到794.73万元，同比减少32.94%至88.82%。 一、本期业 ...

1月28日晚间，有"牙膏第一股"之称的两面针（600249）（600249）披露2025年年度业绩预告，公司预计 2025年年度实现归属于上市公司股东的净利润为500万元到1,000万元，与上年同期相比，将减少7109.88万 元到7609.88万元，同比下降87.67%至93.83%。 公开资料显示，两面针起源于1941年成立的亚洲枧厂等5家小型私营肥皂厂，1978年组建"柳州市牙膏 厂"，2004年在上交所挂牌上市，是A股牙膏行业首家自有品牌上市企业，其牙膏销量曾连续10数年居全 国第一，有"牙膏第一股"之称，其广告拥有较高的国民记忆度。两面针主营业务是日化用品的研发、生产 和销售。公司的主要产品是两面针、沐兰泽、逍遥、芳草等。 此前于2025年10月28日，两面针公布2025年三季报，公司前三季营业收入为8.15亿元，同比上升3.03%； 归母净利润为2349万元，同比下降72.04%；扣非归母净利润为1550万元，同比下降44.81%。其中第三季 度，公司营业收入为2.93亿元，同比上升6.83%；归母净利润为2857万元，同比下降67.34%；扣非归母净 利润为1069万元，同比下降44.16%。 ...

资料图（图片来源： 视觉中国 ） 云南白药 牙膏止血到底靠什么，官方的回应中并未提及。 "6大白药活性因子，具有活血、抑菌、止血、修复、抗炎及骨细胞生长的独特作用，全面保健牙 周。"这是云南白药官网上对其一款牙膏的介绍。 牙膏是云南白药（000538.SZ）健康板块的主要产品。根据云南白药公告，"该产品市场占有率位居全国 第二位、民族品牌第一位"。而"止血"正是云南白药牙膏的重要卖点。 不过，近日一位血液科医生去超市买牙膏，发现云南白药牙膏中含有止血西药成分：氨甲环酸，这令她 心中不解："这种牙膏的止血作用成分，究竟是中草药还是止血处方药？"她将文章发到了网络上，引爆 了舆论。 氨甲环酸是什么？这种西药成分能否添加到牙膏中？云南白药牙膏中起到止血作用的到底是"白药活性 因子"还是氨甲环酸？ 中草药牙膏里起止血作用的是西药成分？ 10月21日，认证为三甲医院血液科执业医师的网友"科普医生博雅"发表文章称，她在云南白药中草药牙 膏成分中发现了氨甲环酸，并指出，这是血液科医生常用的止血药，并且还是处方药。该网友发现，很 多号称能防止牙龈出血的中草药牙膏均含有该成分，因此该网友怀疑这些号称能防止牙龈出血的中草药 牙膏 ...

Group 1: FILA Incident and Response - FILA issued an apology to consumers regarding an incident where a store employee in Zhengzhou improperly noted a customer's complaint about shoe prices in a member group chat [1] - The brand stated that the employee's actions violated their employee conduct guidelines and that they are in communication with the affected customer to resolve the issue [1] Group 2: Store Experience Upgrade - FILA is currently upgrading its store experience, with approximately 30% of its new V6 store format implemented in the first half of the year, leading to significant sales growth [2] - The brand opened its first FILA KIDS art museum store in May and launched a new FILA GOLF store format in August [2] Group 3: Market Pressure and Competitor Performance - Market pressures are evident, as Peak reported significant losses in its domestic direct sales segment, totaling over 130 million yuan from January to July [3] - Anta Sports reported low single-digit positive growth in retail sales for its brand products, while FILA also experienced low single-digit growth, indicating a stark contrast to previous years [3] - Li Ning reported a decline in retail sales, with a mid-single-digit decrease in the third quarter [3] Group 4: Importance of Service and Online Market - In the current market environment, enhancing service quality is crucial for FILA [4] - FILA has found growth in the online market, ranking first in the Tmall sales chart for sports and outdoor products during this year's Double Eleven shopping festival [4] Group 5: Need for Service System Restructuring - FILA may need to reorganize its offline service system to adapt to the changing market dynamics [5]

Core Viewpoint - The company, Two-Mouth Needle, is struggling with its performance, showing a significant decline in net profit and facing challenges in its core business despite a historical reputation as a leading domestic brand [1][4]. Financial Performance - In the first half of 2025, the company reported revenue of 522 million yuan, a year-on-year increase of 1.02%, but the net profit attributable to shareholders was a loss of 5.08 million yuan, primarily due to a 46.2% drop in non-recurring net profit [1][4]. - The main revenue sources for the company include the daily chemical segment, which generated 88 million yuan, and the hotel supplies segment, which contributed 437 million yuan with a net profit of 6.44 million yuan [3]. Historical Context - The company has a long history, tracing back to 1941, and was restructured into a joint-stock company in 1994. It was once the leading domestic toothpaste brand with a market share exceeding 10% around 2000 [3][4]. - In 2024, the daily chemical segment's revenue reached 928 million yuan, but it is significantly overshadowed by competitors like Yunnan Baiyao, which reported 6.526 billion yuan in revenue from its health product segment [3]. Management Changes - In February 2025, the company announced a leadership change, with the retirement of the former chairman and the appointment of Zhou Yunxiang as the new chairman [4]. Future Strategy - The new chairman emphasized a focus on core business, integrating daily chemical and pharmaceutical industries, and leveraging technology for innovation and market expansion [5]. - The company aims to enhance brand value and profitability through comprehensive marketing strategies and the utilization of a health industry fund to support growth in the health sector [5].

Core Viewpoint - The company reported a slight increase in revenue for the first half of 2025, but net profit remains negative, indicating ongoing financial challenges [1] Financial Performance - The company's operating revenue for the first half of 2025 reached 522 million yuan, representing a year-on-year growth of 1.02% [1] - The net profit attributable to shareholders was -5.08 million yuan, compared to -3.47 million yuan in the same period last year [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was 4.81 million yuan, showing a decline of 46.20% year-on-year [1]